OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Cancer is 73. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Outcompeting neighbors for intestinal cancer initiation	630
Gut decisions in CAR T cell therapy	420
Untangling the threads of immunotherapy research	410
Alzheimer’s drug turns macrophages against cancer	410
Enhancing childhood cancer targetability	351
Shooting for multiplexed pathology with Orion	337
Author Correction: Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling	321
Author Correction: Breaking the performance ceiling for neoantigen immunogenicity prediction	316
Breaking frontiers with multidisciplinary cancer research	283
An oncolytic circular RNA therapy	258
Single-cell transcriptomic landscape deciphers olfactory neuroblastoma subtypes and intra-tumoral heterogeneity	247
PARP11 interfer(on)es with CAR T cell efficacy	228
ZFP281 drives a mesenchymal-like dormancy program in early disseminated breast cancer cells that prevents metastatic outgrowth in the lung	215
A low-coverage liquid biopsy for lung cancer	212
Author Correction: RIOK1 phase separation restricts PTEN translation via stress granules activating tumor growth in hepatocellular carcinoma	211
Author Correction: IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR+HER2− breast cancer via CX3CR1+ macrophages	204
Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80	204
Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling	196
A macrophage-activated abscopal effect	161
Considering molecular alterations as pan-cancer tissue-agnostic targets	158
MALAT1 protects dormant tumor cells from immune elimination	156
A single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma	139
The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLC	138
Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms	137
Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer	135

Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial	133
DePICting T cell–APC crosstalk in cancer	132
The cGAS–STING pathway and cancer	132
Beating cancer one carbon at a time	121
Expanding the options for KRAS inhibition	119
Palmitate oxidation drives a pro-metastatic post-translational modification	116
Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor	112
Stress granules shape metabolic reprogramming and drug resistance	111
The importance of being generous	110
Bone marrow progenitor-like cells against leukemia cure	109
A targetable type III immune response with increase of IL-17A expressing CD4+ T cells is associated with immunotherapy-induced toxicity in melanoma	108
Shaping the microenvironment in peritoneal metastases	107
Reflecting on the golden age of cancer research	105
crossNN is an explainable framework for cross-platform DNA methylation-based classification of tumors	105
Adoptively transferred tumor-specific IL-9-producing cytotoxic CD8+ T cells activate host CD4+ T cells to control tumors with antigen loss	105
Impact of context-dependent autophagy states on tumor progression	99
Advancing therapeutics in small-cell lung cancer	97
IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia	95
Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity	94
Determinants of resistance and response to melanoma therapy	93
A tumor-derived type III collagen-rich ECM niche regulates tumor cell dormancy	93
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma	90
Sarcoma ecotypes determine immunotherapy benefit	89
INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas	89
A comeback for checkpoint inhibition in multiple myeloma	89
Innate immunity drives epithelial cell plasticity during prostate tumor formation	89
Antibody avidity meets multiple myeloma	88
Inflammation meets translation in AML	87
Evolving landscape of nasopharyngeal carcinoma therapy	87
Thriving in diverse ecosystems	87
A multiomic atlas identifies a treatment-resistant, bone marrow progenitor-like cell population in T cell acute lymphoblastic leukemia	86
Sex-specific gut microbiota and neutrophil senescence in bladder cancer	86
Clinical implementation of artificial-intelligence-assisted detection of breast cancer metastases in sentinel lymph nodes: the CONFIDENT-B single-center, non-randomized clinical trial	85
Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtypes	85
Circadian regulation of cancer stem cells and the tumor microenvironment during metastasis	85
SCRN1 confers hepatocellular carcinoma resistance to ferroptosis by stabilizing GPX4 via STK38-mediated phosphorylation	84
Cycling back to folate metabolism in cancer	83
Cancer-derived mitochondria fuel fibroblasts to become pro-tumorigenic	83
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer	83
LAG-3 and PD-1 blockade raises the bar for melanoma	82
Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer	81
Integrative single-cell analysis of human colorectal cancer reveals patient stratification with distinct immune evasion mechanisms	80
Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers	79
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling	79
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial	76
Concurrent inhibition of tumor growth and metastasis by a lipidated nanophotosensitizer tracing and disabling tumor extracellular vesicles	76
MCL1 inhibitor BRD-810 kills cancer cells while minimizing risk of cardiotoxicity	74
Radioligand cancer therapy comes to the fore	73
Regulatory T cells play a crucial part in radio-immunotherapy resistance of brain tumors	73
Immunosuppressive dura-derived macrophages in leptomeningeal metastasis	73